Nexalin Technology (NXL) shares rose 15% in recent trading Tuesday after the company announced a planned clinical trial for its Gen-3 Halo headset to treat victims of traumatic brain injury.
The trial is in collaboration with the University of California, San Diego, the company said Tuesday in a statement.
The headset will be used in a virtual clinic model, and the trial will evaluate the effectiveness of the device on brain activity and symptom relief in veterans with mild traumatic brain injury, the company said.
Price: 1.71, Change: +0.23, Percent Change: +15.54
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。